ACW updated Depression Trial Results and implications 

See Actinogen CEO, Dr Steven Gourlay, CMO Dr Dana Hilt and commercial leader Mr Andy Udell present the positive and consistent XanaCIDD depression trial data announced on Monday 26 August, how the trial results teach about Xanamem’s cortisol control mechanism, and the outlook for Actinogen’s depression trial program.